SCHEMBL7052677

SCHEMBL7052677

c1csc(C2(CCN3CCCCC3)C3CC4CC(C3)CC2C4)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PRCP P42785 1/20 0.40
KCNH2 Q12809 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
SLC6A2 P23975 1/20 0.35
CHRM2 P08172 2/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
HSD11B1 P28845 2/20 0.33
OPRM1 P35372 1/20 0.32
OPRL1 P41146 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
ADRA2A P08913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7057088 0.99 MEN1 (0.39) SIGMAR1MEN1KMT2APRCPKCNH2
Hydrochloric Acid SCHEMBL7054114 0.97 MEN1 (0.38) SIGMAR1MEN1KMT2APRCPKCNH2
SCHEMBL6682913 0.87 HTT (0.43) MEN1KMT2A
Hydrochloric Acid SCHEMBL6681764 0.86 ALDH1A1 (0.44) MEN1KMT2A
SCHEMBL6684471 0.77 SLC6A2 (0.41) SLC6A2CHRM2CHRM4CHRM5CHRM1
SCHEMBL6682839 0.77 HSD11B1 (0.39) MEN1KMT2ASLC6A2CHRM2CHRM4
Hydrochloric Acid SCHEMBL6680117 0.76 SLC6A2 (0.40) SLC6A2CHRM2CHRM4CHRM5CHRM1
SCHEMBL7082000 0.75 SLC6A2 (0.39) SLC6A2CHRM2CHRM4CHRM5CHRM1
Hydrochloric Acid SCHEMBL7136533 0.74 SLC6A2 (0.38) SLC6A2CHRM2CHRM4CHRM5CHRM1
Hydrochloric Acid SCHEMBL6894589 0.73 SLC6A2 (0.45) SLC6A2CHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1305306-A2 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION VERNALIS RESEARCH LIMITED (GB) 2003-05-02 EP claimed
WO-2002008219-A2 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION VERNALIS RESEARCH LIMITED (GB) 2002-01-31 WO claimed
EP-1305306-A2 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION VERNALIS RESEARCH LIMITED (GB) 2003-05-02 EP disclosed
WO-2002008219-A2 2-ADAMANTYLETHYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION VERNALIS RESEARCH LIMITED (GB) 2002-01-31 WO disclosed